Microplasmin receives orphan drug protection

Article

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Recent Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
Data demonstrates efficacy of FDA-approved therapy for treating amblyopia in children

Data demonstrates efficacy of FDA-approved therapy for treating amblyopia in children

Article
ROP: Treating and preventing blindness in preterm babies

ROP: Treating and preventing blindness in preterm babies

Podcast
Vyluma meets with FDA to discuss atropine sulfate ophthalmic solution 0.01% for the treatment of pediatric myopia

Vyluma meets with FDA to discuss atropine sulfate ophthalmic solution 0.01% for the treatment of pediatric myopia

Article
Managing a changing landscape of IRD pediatric cases

Managing a changing landscape of IRD pediatric cases

Podcast
Dopavision reports positive results from MyopiaX-1 trial on pediatric myopia management

Dopavision reports positive results from MyopiaX-1 trial on pediatric myopia management

Article
Bipartisan proposal introduced in US House to address children's vision impairment

Bipartisan proposal introduced in US House to address children's vision impairment

Article
© 2024 MJH Life Sciences

All rights reserved.